Hepatitis A hospitalizations among kidney transplant recipients in the United States: nationwide inpatient sample 2005-2014.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
29
6
2021
Statut:
ppublish
Résumé
This study aimed to evaluate the hospitalization rate for Hepatitis A virus (HAV) among kidney transplant (KTx) recipients and its outcomes as well as resource utilization. The 2005-2014 National Inpatient Sample database was used to identify all hospitalized KTx recipients with an associated diagnosis of HAV. The hospital mortality, resource utilization, and associated liver conditions were compared between patients with and without HAV, adjusting for potential confounders. Of 871 024 KTx recipients identified, 204 had HAV. The overall inpatient prevalence of HAV in KTx recipients over 10 years in the United States was 23.42 cases per 100 000 admissions. There were no statistically significant changes in the inpatient prevalence of HAV in KTx recipients during the study period (P = 0.77), ranging from 9.2 to 34.3 per 100 000 admissions. Among hospitalized KTx recipients with HAV, 27.9% were from Northeast, 29.2% were from Midwest, 23.8% were from South, and 19.1% were from West. HAV was not significantly associated with increased hospital mortality, multiorgan failure, need for abdominal ultrasound, hospital length of stay, and total hospitalization costs and charges when compared with those without HAV. However, it is significantly associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure. Overall, inpatient prevalence of HAV in KTx recipients in the United States (years 2005-2014) was 23.42 cases per 100 000 admissions. Hospitalization for HAV after KTx is associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure.
Sections du résumé
BACKGROUND
This study aimed to evaluate the hospitalization rate for Hepatitis A virus (HAV) among kidney transplant (KTx) recipients and its outcomes as well as resource utilization.
METHODS
The 2005-2014 National Inpatient Sample database was used to identify all hospitalized KTx recipients with an associated diagnosis of HAV. The hospital mortality, resource utilization, and associated liver conditions were compared between patients with and without HAV, adjusting for potential confounders.
RESULTS
Of 871 024 KTx recipients identified, 204 had HAV. The overall inpatient prevalence of HAV in KTx recipients over 10 years in the United States was 23.42 cases per 100 000 admissions. There were no statistically significant changes in the inpatient prevalence of HAV in KTx recipients during the study period (P = 0.77), ranging from 9.2 to 34.3 per 100 000 admissions. Among hospitalized KTx recipients with HAV, 27.9% were from Northeast, 29.2% were from Midwest, 23.8% were from South, and 19.1% were from West. HAV was not significantly associated with increased hospital mortality, multiorgan failure, need for abdominal ultrasound, hospital length of stay, and total hospitalization costs and charges when compared with those without HAV. However, it is significantly associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure.
CONCLUSION
Overall, inpatient prevalence of HAV in KTx recipients in the United States (years 2005-2014) was 23.42 cases per 100 000 admissions. Hospitalization for HAV after KTx is associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure.
Identifiants
pubmed: 32267653
doi: 10.1097/MEG.0000000000001598
pii: 00042737-202005000-00017
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
650-655Références
Aggarwal R, Goel A. Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis. 2015; 28:488–496
Linder KA, Malani PN. Hepatitis A. JAMA. 2017; 318:2393
Hettmann A, Juhász G, Dencs Á, Tresó B, Rusvai E, Barabás É, Takács M. Phylogenetic analysis of a transfusion-transmitted hepatitis A outbreak. Virus Genes. 2017; 53:15–20
Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology. 2010; 53:15–19
Koenig KL, Shastry S, Burns MJ. Hepatitis A virus: essential knowledge and a novel identify-isolate-inform tool for frontline healthcare providers. West J Emerg Med. 2017; 18:1000–1007
Nainan OV, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis a virus infection: a molecular approach. Clin Microbiol Rev. 2006; 19:63–79
Sharapov UM, Kentenyants K, Groeger J, Roberts H, Holmberg SD, Collier MG. Hepatitis A infections among food handlers in the united states, 1993-2011. Public Health Rep. 2016; 131:26–29
Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: epidemiology and prevention in developing countries. World J Hepatol. 2012; 4:68–73
Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998; 27:881–886
Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med. 2004; 350:476–481
Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001; 14:38–58
O’Grady J. Management of acute and fulminant hepatitis A. Vaccine. 1992; 10Suppl 1S21–S23
Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, et al.; US Acute Liver Failure Study Group. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology. 2006; 44:1589–1597
Yoshida Y, Okada Y, Suzuki A, Kakisaka K, Miyamoto Y, Miyasaka A, et al. Fatal acute hepatic failure in a family infected with the hepatitis A virus subgenotype IB: a case report. Medicine (Baltimore). 2017; 96:e7847
Collier MG, Tong X, Xu F. Hepatitis A hospitalizations in the United States, 2002-2011. Hepatology. 2015; 61:481–485
Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med. 2000; 154:763–770
Mackinney-Novelo I, Barahona-Garrido J, Castillo-Albarran F, Santiago-Hernández JJ, Méndez-Sánchez N, Uribe M, Chávez-Tapia N. Clinical course and management of acute hepatitis A infection in adults. Ann Hepatol. 2012; 11:652–657
Keeffe EB. Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases. Trans Am Clin Climatol Assoc. 2006; 117:227–237; discussion 237
Jeon HJ, Ro H, Jeong JC, Koo TY, Han M, Min SI, et al. Efficacy and safety of hepatitis A vaccination in kidney transplant recipients. Transpl Infect Dis. 2014; 16:511–515
Stark K, Günther M, Neuhaus R, Reinke P, Schröder K, Linnig S, Bienzle U. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis. 1999; 180:2014–2017
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45:613–619
Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the united states in the era of vaccination. JAMA. 2005; 294:194–201
Bell BP, Margolis HS, Shapiro CN. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996; 45:1–30
Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55:1–23
Nelson NP, Yankey D, Singleton JA, Elam-Evans LD. Hepatitis A vaccination coverage among adolescents (13-17-years) in the united states, 2008-2016. Vaccine. 2018; 36:1650–1659
Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19-35 months--United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61:689–696
Dorell CG, Yankey D, Byrd KK, Murphy TV. Hepatitis a vaccination coverage among adolescents in the United States. Pediatrics. 2012; 129:213–221
Rhodes SD, Yee LJ, Hergenrather KC. Hepatitis A vaccination among young african american men who have sex with men in the deep south: psychosocial predictors. J Natl Med Assoc. 2003; 95:31S–36S
Lu PJ, Byrd KK, Murphy TV. Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States. Vaccine. 2013; 31:2348–2357
Murphy TV, Denniston MM, Hill HA, McDonald M, Klevens MR, Elam-Evans LD, et al. Progress toward eliminating hepatitis A disease in the United States. MMWR Suppl. 2016; 65:29–41
Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003; 16:357–364
Donato-Santana C, Theodoropoulos NM. Immunization of solid organ transplant candidates and recipients: a 2018 update. Infect Dis Clin North Am. 2018; 32:517–533
Löbermann M, Boršo D, Hilgendorf I, Fritzsche C, Zettl UK, Reisinger EC. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012; 11:212–218
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9Suppl 3S1–S155
Mariya FA, de Mello Perez R, Silva AE, Pestana JO, Ferraz ML. Prevalence of previous hepatitis A virus infection in renal transplant patients with hepatitis C: evidence of persistent anti-hepatitis A virus immune response. Transplant Proc. 2004; 36:1500–1501
Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to hepatitis A vaccination in immunocompromised travelers. J Infect Dis. 2015; 212:378–385
Günther M, Stark K, Neuhaus R, Reinke P, Schröder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation. 2001; 71:477–479
Chow J, Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis. 2009; 49:1550–1556
Fleischmann EH, Kruppenbacher J, Bock HL, Weber M. Active immunization against hepatitis A in dialysis patients. Nephrol Dial Transplant. 2002; 17:1825–1828
Foster MA. Increase in hepatitis A virus infections—United States, 2013–2018. MMWR Morb Mortal Wkly Rep. 2019; 68
Foster M. Changing Epidemiology of Hepatitis A Virus Infections––United States, 2007–2017. 2018, IDWeek 2018: Idsa
Snyder MR, McGinty MD, Shearer MP, Meyer D, Hurtado C, Nuzzo JB. Outbreaks of hepatitis A in US communities, 2017-2018: firsthand experiences and operational lessons from public health responses. Am J Public Health. 2019; 109:S297–S302
Peak CM, Stous SS, Healy JM, Hofmeister MG, Lin Y, Ramachandran S, et al. Homelessness and hepatitis A – San Diego County, 2016-2018. Clin Infect Dis. 2019; pii:ciz788
Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the advisory committee on immunization practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep. 2019; 68:153–156